দেশ: মার্কিন যুক্তরাষ্ট্র
ভাষা: ইংরেজি
সূত্র: NLM (National Library of Medicine)
CLINDAMYCIN PALMITATE HYDROCHLORIDE (UNII: VN9A8JM7M7) (Clindamycin - UNII:3U02EL437C)
Padagis US LLC
CLINDAMYCIN PALMITATE HYDROCHLORIDE
Clindamycin 75 mg in 5 mL
ORAL
PRESCRIPTION DRUG
Clindamycin palmitate hydrochloride for oral solution is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pe
Clindamycin Palmitate Hydrochloride for Oral Solution, USP is available in bottles of 100 mL (NDC 0574-0129 -01). When reconstituted as directed, each bottle yields a solution containing 75 mg of clindamycin per 5 mL. Rx only
Abbreviated New Drug Application
CLINDAMYCIN PALMITATE HYDROCHLORIDE- CLINDAMYCIN PALMITATE HYDROCHLORIDE GRANULE, FOR SOLUTION PADAGIS US LLC ---------- CLINDAMYCIN PALMITATE HYDROCHLORIDE FOR ORAL SOLUTION, USP To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin palmitate hydrochloride for oral solution and other antibacterial drugs, clindamycin palmitate hydrochloride for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. _Not for Injection_ WARNING _Clostridium difficile _associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of _C. difficile._ Because clindamycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. _C. difficile _produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of _C._ _difficile _cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against _C. difficile _may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of _C. difficile_, and surgical evaluation should be instituted as clinically indicated. DESCRIPTION Clindamycin palmi সম্পূর্ণ নথি পড়ুন